Tekla Total Liab vs Net Debt Analysis

HQL Stock

USD 13.08 0.02 0.15%

Tekla Life financial indicator trend analysis is much more than just breaking down Tekla Life Sciences prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Tekla Life Sciences is a good investment. Please check the relationship between Tekla Life Total Liab and its Net Debt accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Tekla Life Sciences. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in producer price index.

Total Liab vs Net Debt

Total Liab vs Net Debt Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Tekla Life Sciences Total Liab account and Net Debt. At this time, the significance of the direction appears to have weak contrarian relationship.

The correlation between Tekla Life's Total Liab and Net Debt is -0.01. Overlapping area represents the amount of variation of Total Liab that can explain the historical movement of Net Debt in the same time period over historical financial statements of Tekla Life Sciences, assuming nothing else is changed. The correlation between historical values of Tekla Life's Total Liab and Net Debt is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Liab of Tekla Life Sciences are associated (or correlated) with its Net Debt. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Debt has no effect on the direction of Total Liab i.e., Tekla Life's Total Liab and Net Debt go up and down completely randomly.

Correlation Coefficient

-0.01

Relationship Direction	Negative
Relationship Strength	Insignificant

View All Relationships

Total Liab

The total amount of all liabilities that a company has, including both short-term and long-term liabilities.

Net Debt

The total debt of a company minus its cash and cash equivalents. It represents the actual debt burden on the company after accounting for the liquid assets it holds.

Most indicators from Tekla Life's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Tekla Life Sciences current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Tekla Life Sciences. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in producer price index.

At this time, Tekla Life's Enterprise Value Over EBITDA is quite stable compared to the past year. Enterprise Value Multiple is expected to rise to 18.05 this year, although the value of Selling General Administrative will most likely fall to about 692 K.

	2021	2022	2023	2024 (projected)
Total Operating Expenses	1.4M	1.2M	1.3M	861.3K
Cost Of Revenue	5.5M	5.2M	6.0M	3.9M

Total Operating Expenses Cost Of Revenue

Tekla Life fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Debt	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Total Liab	Total Current Assets	Common Stock	Net Receivables	Other Stockholder Equity	Net Tangible Assets	Retained Earnings	Long Term Investments	Other Liab	Other Current Assets	Short Term Investments	Capital Stock	Non Current Liabilities Total
Total Assets		0.17	0.51	1.0	0.3	0.5	-0.22	1.0	-0.96	-0.7	0.21	0.08	0.81	0.33	0.2	0.08	0.2	0.29	0.75	0.15	0.73	0.7	-0.09	0.24	-0.33	0.18
Other Current Liab	0.17		0.25	0.17	0.35	-0.22	-0.14	0.18	-0.23	0.07	0.12	0.0	-0.18	0.19	-0.32	0.0	-0.31	-0.14	0.36	0.51	0.4	-0.14	0.15	-0.18	0.06	0.75
Total Current Liabilities	0.51	0.25		0.49	0.01	0.71	0.18	0.52	-0.46	-0.25	-0.25	-0.44	0.6	0.6	0.1	-0.44	0.11	0.61	0.34	-0.19	0.39	0.32	-0.54	0.68	-0.62	0.47
Total Stockholder Equity	1.0	0.17	0.49		0.31	0.49	-0.23	1.0	-0.96	-0.7	0.22	0.09	0.8	0.3	0.21	0.09	0.21	0.28	0.76	0.15	0.73	0.7	-0.07	0.21	-0.31	0.15
Net Debt	0.3	0.35	0.01	0.31		0.33	-0.97	0.31	-0.33	-0.1	0.84	-0.45	0.17	-0.01	-0.26	-0.45	-0.23	0.38	0.38	0.26	0.4	0.07	-0.06	0.01	-0.47	-0.11
Accounts Payable	0.5	-0.22	0.71	0.49	0.33		-0.28	0.5	-0.47	-0.33	0.2	-0.62	0.71	0.36	0.22	-0.62	0.24	0.87	0.31	-0.41	0.35	0.35	-0.63	0.71	-0.86	-0.16
Cash	-0.22	-0.14	0.18	-0.23	-0.97	-0.28		-0.23	0.24	0.08	-0.88	0.39	-0.13	0.13	0.21	0.39	0.18	-0.32	-0.28	-0.21	-0.29	-0.06	0.0	0.06	0.39	0.31
Non Current Assets Total	1.0	0.18	0.52	1.0	0.31	0.5	-0.23		-0.96	-0.69	0.22	0.06	0.8	0.34	0.17	0.06	0.17	0.29	0.76	0.15	0.74	0.69	-0.1	0.25	-0.33	0.18
Non Currrent Assets Other	-0.96	-0.23	-0.46	-0.96	-0.33	-0.47	0.24	-0.96		0.7	-0.24	-0.1	-0.69	-0.37	-0.15	-0.1	-0.15	-0.25	-0.75	-0.19	-0.73	-0.57	0.06	-0.2	0.3	-0.23
Other Assets	-0.7	0.07	-0.25	-0.7	-0.1	-0.33	0.08	-0.69	0.7		-0.06	-0.13	-0.68	-0.16	-0.21	-0.13	-0.21	-0.22	-0.78	-0.28	-0.74	-0.88	0.15	-0.22	0.22	0.03
Cash And Short Term Investments	0.21	0.12	-0.25	0.22	0.84	0.2	-0.88	0.22	-0.24	-0.06		-0.17	0.14	-0.18	-0.22	-0.17	-0.23	0.17	0.17	0.05	0.19	0.02	-0.04	-0.08	-0.24	-0.31
Common Stock Total Equity	0.08	0.0	-0.44	0.09	-0.45	-0.62	0.39	0.06	-0.1	-0.13	-0.17		-0.22	-0.22	0.27	1.0	0.23	-0.88	0.01	0.37	-0.11	0.04	0.7	-0.64	0.89	0.1
Common Stock Shares Outstanding	0.81	-0.18	0.6	0.8	0.17	0.71	-0.13	0.8	-0.69	-0.68	0.14	-0.22		0.32	0.35	-0.22	0.35	0.59	0.51	-0.24	0.53	0.8	-0.51	0.61	-0.6	-0.09
Total Liab	0.33	0.19	0.6	0.3	-0.01	0.36	0.13	0.34	-0.37	-0.16	-0.18	-0.22	0.32		-0.17	-0.22	-0.17	0.28	0.11	-0.05	0.2	0.1	-0.45	0.69	-0.34	0.68
Total Current Assets	0.2	-0.32	0.1	0.21	-0.26	0.22	0.21	0.17	-0.15	-0.21	-0.22	0.27	0.35	-0.17		0.27	1.0	0.03	0.03	-0.19	-0.1	0.23	0.04	-0.01	0.03	-0.29
Common Stock	0.08	0.0	-0.44	0.09	-0.45	-0.62	0.39	0.06	-0.1	-0.13	-0.17	1.0	-0.22	-0.22	0.27		0.23	-0.88	0.01	0.37	-0.11	0.04	0.7	-0.64	0.89	0.1
Net Receivables	0.2	-0.31	0.11	0.21	-0.23	0.24	0.18	0.17	-0.15	-0.21	-0.23	0.23	0.35	-0.17	1.0	0.23		0.06	0.04	-0.17	-0.08	0.23	0.05	-0.01	0.0	-0.3
Other Stockholder Equity	0.29	-0.14	0.61	0.28	0.38	0.87	-0.32	0.29	-0.25	-0.22	0.17	-0.88	0.59	0.28	0.03	-0.88	0.06		0.23	-0.47	0.33	0.28	-0.79	0.77	-0.99	-0.18
Net Tangible Assets	0.75	0.36	0.34	0.76	0.38	0.31	-0.28	0.76	-0.75	-0.78	0.17	0.01	0.51	0.11	0.03	0.01	0.04	0.23		0.46	0.97	0.71	0.08	0.0	-0.25	0.18
Retained Earnings	0.15	0.51	-0.19	0.15	0.26	-0.41	-0.21	0.15	-0.19	-0.28	0.05	0.37	-0.24	-0.05	-0.19	0.37	-0.17	-0.47	0.46		0.38	0.16	0.57	-0.52	0.41	0.34
Long Term Investments	0.73	0.4	0.39	0.73	0.4	0.35	-0.29	0.74	-0.73	-0.74	0.19	-0.11	0.53	0.2	-0.1	-0.11	-0.08	0.33	0.97	0.38		0.67	-0.06	0.13	-0.36	0.23
Other Liab	0.7	-0.14	0.32	0.7	0.07	0.35	-0.06	0.69	-0.57	-0.88	0.02	0.04	0.8	0.1	0.23	0.04	0.23	0.28	0.71	0.16	0.67		-0.19	0.27	-0.27	-0.1
Other Current Assets	-0.09	0.15	-0.54	-0.07	-0.06	-0.63	0.0	-0.1	0.06	0.15	-0.04	0.7	-0.51	-0.45	0.04	0.7	0.05	-0.79	0.08	0.57	-0.06	-0.19		-0.93	0.79	-0.02
Short Term Investments	0.24	-0.18	0.68	0.21	0.01	0.71	0.06	0.25	-0.2	-0.22	-0.08	-0.64	0.61	0.69	-0.01	-0.64	-0.01	0.77	0.0	-0.52	0.13	0.27	-0.93		-0.78	0.15
Capital Stock	-0.33	0.06	-0.62	-0.31	-0.47	-0.86	0.39	-0.33	0.3	0.22	-0.24	0.89	-0.6	-0.34	0.03	0.89	0.0	-0.99	-0.25	0.41	-0.36	-0.27	0.79	-0.78		0.12
Non Current Liabilities Total	0.18	0.75	0.47	0.15	-0.11	-0.16	0.31	0.18	-0.23	0.03	-0.31	0.1	-0.09	0.68	-0.29	0.1	-0.3	-0.18	0.18	0.34	0.23	-0.1	-0.02	0.15	0.12

Click cells to compare fundamentals

Tekla Life Account Relationship Matchups

Tekla Life fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	484.2M	534.2M	414.7M	402.6M	463.0M	335.6M
Other Current Liab	(2.8M)	567.3K	10.7M	(5.1M)	(5.9M)	(5.6M)
Total Current Liabilities	2.8M	581.2K	10.7M	5.1M	5.9M	3.2M
Total Stockholder Equity	483.6M	523.4M	397.9M	401.9M	462.2M	332.0M
Net Debt	5.0M	1.3M	10.6K	(477.0)	(548.55)	(575.98)
Cash	(5.0M)	990.0	445.0	477.0	429.3	407.84
Non Current Assets Total	484.0M	534.0M	414.1M	397.5M	457.2M	332.8M
Non Currrent Assets Other	(484.0M)	(534.0M)	(414.1M)	(397.5M)	(357.8M)	(375.7M)
Other Assets	118.6K	33.0K	25.4K	26.3K	23.7K	22.5K
Cash And Short Term Investments	5.0M	990.0	445.0	477.0	548.55	521.12
Common Stock Shares Outstanding	23.8M	24.3M	25.7M	26.8M	30.8M	19.2M
Liabilities And Stockholders Equity	484.2M	534.2M	414.7M	402.6M	463.0M	335.6M
Total Liab	595.2K	10.7M	16.8M	667.0K	767.0K	728.7K
Total Current Assets	73.9K	144.7K	623.9K	5.0M	5.8M	6.1M
Common Stock	238.8K	246.7K	256.8K	267.9K	308.1K	292.7K
Net Receivables	73.9K	143.7K	623.5K	5.0M	5.8M	6.1M
Other Stockholder Equity	356.3M	372.5M	388.1M	403.1M	463.6M	486.8M
Net Tangible Assets	383.7M	483.6M	523.4M	397.9M	457.6M	449.7M
Retained Earnings	127.0M	150.7M	9.5M	(1.5M)	(1.7M)	(1.6M)
Long Term Investments	484.0M	534.0M	414.1M	397.5M	457.2M	444.7M
Other Current Assets	(5.0M)	(17.3M)	(33.6M)	(20.3M)	(18.3M)	(17.3M)
Short Term Investments	5.0M	17.2M	32.9M	15.2M	17.5M	12.9M
Capital Stock	238.8K	246.7K	256.8K	267.9K	241.1K	229.1K
Non Current Liabilities Total	569.2K	9.4M	5.1M	667.0K	600.3K	570.3K

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether Tekla Life Sciences is a strong investment it is important to analyze Tekla Life's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Tekla Life's future performance. For an informed investment choice regarding Tekla Stock, refer to the following important reports:

How To Invest In Tekla

Details

Is Tekla Stock a good investment?

Details

What is Tekla Life's Net Worth?

Details

Largest Asset Management & Custody Banks Companies

View

Largest Financial Services Companies

View

Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Tekla Life Sciences. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in producer price index.

You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.

Complementary Tools for Tekla Stock analysis

When running Tekla Life's price analysis, check to measure Tekla Life's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tekla Life is operating at the current time. Most of Tekla Life's value examination focuses on studying past and present price action to predict the probability of Tekla Life's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tekla Life's price. Additionally, you may evaluate how the addition of Tekla Life to your portfolios can decrease your overall portfolio volatility.

	Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments
	Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
	Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges
	Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
	Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon
	ETFs Find actively traded Exchange Traded Funds (ETF) from around the world
	Share Portfolio Track or share privately all of your investments from the convenience of any device
	Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years
	ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments
	Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios

Is Tekla Life's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Tekla Life. If investors know Tekla will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Tekla Life listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

(0.66)

Dividend Share

1.3

Earnings Share

0.79

Revenue Per Share

0.134

Quarterly Revenue Growth

0.344

The market value of Tekla Life Sciences is measured differently than its book value, which is the value of Tekla that is recorded on the company's balance sheet. Investors also form their own opinion of Tekla Life's value that differs from its market value or its book value, called intrinsic value, which is Tekla Life's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Tekla Life's market value can be influenced by many factors that don't directly affect Tekla Life's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Tekla Life's value and its price as these two are different measures arrived at by different means. Investors typically determine if Tekla Life is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Tekla Life's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Tekla Total Liab vs Net Debt Analysis

Total Liab vs Net Debt

Total Liab vs Net Debt Correlation Analysis

Correlation Coefficient

Total Liab

Net Debt

Tekla Life fundamental ratios Correlations

Tekla Life Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Tekla Life fundamental ratios Accounts

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

Complementary Tools for Tekla Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Stockholder Equity	+ 1.0	Total Assets
Non Current Assets Total	+ 1.0	Total Assets
Non Current Assets Total	+ 1.0	Total Stockholder Equity
Common Stock	+ 1.0	Common Stock Total Equity
Net Receivables	+ 1.0	Total Current Assets
Long Term Investments	+ 0.97	Net Tangible Assets

Capital Stock	- 0.99	Other Stockholder Equity
Cash	- 0.97	Net Debt
Non Currrent Assets Other	- 0.96	Non Current Assets Total
Non Currrent Assets Other	- 0.96	Total Stockholder Equity
Non Currrent Assets Other	- 0.96	Total Assets
Short Term Investments	- 0.93	Other Current Assets